Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?

Jiralerspong S, Gonzalez-Angulo AM, Hung MC.

Cell Cycle. 2009 Sep 1;8(17):2681. Epub 2009 Sep 1. No abstract available.


Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.

Cell Cycle. 2009 Jul 1;8(13):2031-40. Epub 2009 Jul 21.


Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.

Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F.

Sci Rep. 2016 Jan 5;6:18673. doi: 10.1038/srep18673.


The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention.

Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR.

Biochim Biophys Acta. 2014 Jun;1840(6):1943-57. doi: 10.1016/j.bbagen.2014.01.023. Epub 2014 Jan 23.


Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.

Guo Q, Liu Z, Jiang L, Liu M, Ma J, Yang C, Han L, Nan K, Liang X.

Mol Med Rep. 2016 Mar;13(3):2590-6. doi: 10.3892/mmr.2016.4830. Epub 2016 Jan 29.


Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.


Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.

Thompson AM.

Clin Cancer Res. 2014 May 15;20(10):2508-15. doi: 10.1158/1078-0432.CCR-13-0354. Epub 2014 Mar 28.


LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.

Li C, Liu VW, Chan DW, Yao KM, Ngan HY.

Int J Gynecol Cancer. 2012 Jan;22(1):15-22. doi: 10.1097/IGC.0b013e3182322834.


Metabolic roles of AMPK and metformin in cancer cells.

Choi YK, Park KG.

Mol Cells. 2013 Oct;36(4):279-87. doi: 10.1007/s10059-013-0169-8. Epub 2013 Jun 19. Review.


Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.

Cai H, Zhang Y, Han TK, Everett RS, Thakker DR.

Int J Cancer. 2016 May 1;138(9):2281-92. doi: 10.1002/ijc.29965. Epub 2016 Jan 8.


Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.

Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z.

Mol Cell Biochem. 2014 Jan;386(1-2):63-71. doi: 10.1007/s11010-013-1845-x. Epub 2013 Oct 6.


Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.

Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V.

Breast Cancer Res. 2015 Mar 3;17:32. doi: 10.1186/s13058-015-0540-0.


Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG.

Br J Pharmacol. 2011 Mar;162(5):1096-108. doi: 10.1111/j.1476-5381.2010.01101.x.


Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA.

Curr Mol Med. 2010 Oct;10(7):674-91.


Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.

Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G, Wei J.

Int J Mol Med. 2015 Jul;36(1):204-14. doi: 10.3892/ijmm.2015.2217. Epub 2015 May 21.


Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.

Guppy A, Jamal-Hanjani M, Pickering L.

Future Oncol. 2011 Jun;7(6):727-36. doi: 10.2217/fon.11.49. Review.


Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.

Wang Y, Wei J, Li L, Fan C, Sun Y.

Oncol Res. 2014;22(4):193-201. doi: 10.3727/096504015X14348950540999.


Metformin: a therapeutic opportunity in breast cancer.

Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Review.


Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.

Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP.

Breast Cancer Res Treat. 2010 Sep;123(2):333-44. doi: 10.1007/s10549-009-0647-z. Epub 2009 Nov 22.


Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.

Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC, Zhang H.

Cell Death Dis. 2014 Feb 27;5:e1088. doi: 10.1038/cddis.2014.59.

Supplemental Content

Support Center